Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats

Figure 3 Effect of berberine on hepatic LKB-1 protein expression. Western blot analyses of LKB-1 levels in liver tissues of normal control rats, model rats and diabetic rats treated with berberine, AICAR and metformin. A: Representative blots for each group are shown; B: Each bar is expressed as LKB-1/β-actin and represents the mean ± SD (n = 8). ^aP < 0.05 vs the normal control group; ^cP < 0.05 vs the model group (by ANOVA).